Integrated Biotherapeutics Inc awarded $6.6 million to develop Filovirus vaccine
The grant was awarded to Integrated Biotherapeutics by the National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine hat will protect against all ebola viruses. The research is being led by Co-Principal Investigators Dr. M. Javad Aman, Chief Scientific Officer at IBT, and Drs. Erica Ollmann Saphire and William R. Schief at The Scripps Research Institute (TSRI),
\"This award will enable us to address a pressing global public health need, namely a single vaccine that can protect against all ebolaviruses. To meet this challenge, we have assembled a unique team of experts in immunogen design, structural biology, vaccine development and animal models of filovirus infection,\" said Dr. M. Javad Aman.
\"A novel aspect of the program will be the use of state-of-the-art imaging and computational approaches. This design work will help us craft a vaccine to steer the immune response in the right directions,\" added Dr. Erica Ollmann Saphire.
\"We are excited to participate in this collaboration and to test novel immunogen design strategies for their ability to focus antibody responses to conserved epitopes on ebolaviruses. This will be a fantastic test for structure-based vaccine design, and it may give us insights on how to make vaccines for other more variable viruses,\" added Dr. William Schief.